An investigation into the importance of "very rapid dissolution" criteria for drug bioequivalence demonstration using gastrointestinal simulation technology

AAPS Journal

Volumn 11, Issue 2, 2009, Pages 381-384

  Kovačević, Ivan ^a   Parojčić, Jelena ^b   Tubić Grozdanis, Marija ^c   Langguth, Peter ^c  

^a Medicines and Medical Devices Agency of Serbia   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

BCS; Bioequivalence; Dissolution; Gastrointestinal simulation

Indexed keywords

KETOPROFEN; LOSARTAN; PREDNISONE; PROPRANOLOL;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPUTER PREDICTION; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; INFORMATION PROCESSING; INFORMATION RETRIEVAL; INTESTINE TRANSIT TIME; MAXIMUM PLASMA CONCENTRATION; STOMACH EMPTYING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; COMPUTER SIMULATION; DIGESTIVE SYSTEM; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; KETOPROFEN; KINETICS; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SOLUBILITY; THERAPEUTIC EQUIVALENCY;

EID: 68249155028     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9114-3     Document Type: Article

References (16)

1. FDA/CDER. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Washington, DC: FDA; 2000.
2. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-20.
3. Martinez MN, Amidon GL. a mechanistic approach to understanding the effects affecting drug absorption: A review of fundamentals. J Clin Pharmacol. 2002;42:620-43.
4. FDA/CDER. Guidance for industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Washington, DC: FDA; 2003.
5. EMEA/CHMP. Note for guidance on the investigation of bioavailability and bioequivalence. London: EMEA; 2001.
6. Jantratid E, Prekongpans S, Amidon GL, Dressman JB. Feasibility of biowaiver extension to biopharmaceutics classification system III drug products: Cimetidine. Clin Pharmacokinet. 2006;45:385-9.
7. Tubic-Grozdanis M, Bolger M, Langguth P. Application of gastrointestinal simulation for extensions of biowaivers of highly permeable compounds. AAPS Journal. 2008;10:213-26.
8. Cook J, Addicks W, Wu YH. Application of the biopharmaceutical classification system in clinical drug development - an industrial view. AAPS Journal. 2008;10:306-10.
9. ICH. ICH Harmonised Tripartite Guideline - specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances (ICH Q6A). Geneva: ICH; 1999.
10. EMEA/CHMP. Guideline on the investigation of bioequivalence. London: EMEA; 2008.
11. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50:S41-S67.
12. Moffat AC, Osselton MD, Widdop B, Galichet LY, editors. Clarke's Analysis of Drugs and Poisons. 3rd ed. London: Pharmaceutical; 2004.
13. Therapeutic Systems Research Laboratories (TSRL inc.), Biopharmaceutics Classification System results for losartan (http://www.tsrlinc.com/ services/bcs/results.cfm; access date December 9th, 2008).
14. Summary of Product Characteristics (SPC), Cozaar Film-Coated Tablets 100 mg, Merck Sharp and Dohme (revision August 2007). IPHA medicines compendium (www.medicines.ie; access date December 9th, 2008).
15. Rowland M, Tozer TN. Clinical pharmacokinetics concepts and applications. Pittsburgh: Williams and Wilkins; 1995.
16. Polli JE, Yu LX, Cook JA. Summary workshop report: Biopharmaceutics classification system-implementation challenges and extension opportunities. J Pharm Sci. 2004;93:1375-81.